Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

14.02 -0.01 (-0.07%)
Streaming Delayed Price Updated: 10:38 AM EST, Jan 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Janux Therapeutics, Inc. - Common Stock

< Previous 1 2 Next >
News headline image
Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study
From Janux Therapeutics
Via Business Wire
News headline image
Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual R&D Day on July 24, 2025
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Appoints Janeen Doyle as Chief Corporate and Business Development Officer
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Initiates Phase 1b Expansion Studies with JANX007 in Patients with Prostate Cancer and Provides Program Updates
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Pre-Funded Warrants Including Full Exercise of Underwriters’ Option to Purchase Additional Shares for Total Gross Proceeds of $402.5 Million
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Pricing of $350.0 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Proposed Public Offering
From Janux Therapeutics
Via Business Wire
News headline image
Janux Announces Doses Selected for Phase 1b Expansion Trials Supported by Encouraging Efficacy and Safety Profile Observed in Phase 1a Dose Escalation for JANX007 in mCRPC
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data in Phase 1a Dose Escalation for JANX007 in mCRPC and Doses Selected for Phase 1b Expansion Studies
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Updates to Board of Directors
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Pricing of $296.5 Million Underwritten Public Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Proposed Public Offering of Common Stock
From Janux Therapeutics
Via Business Wire
News headline image
Janux Announces Encouraging Safety and Efficacy Data in Ongoing Dose Escalation Trials for PSMAxCD3-TRACTr JANX007 in mCRPC and EGFRxCD3-TRACTr JANX008 in Solid Tumors
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics to Host Virtual Event Discussing Updated Clinical Data for PSMA-TRACTr JANX007 and EGFR-TRACTr JANX008
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Promotes Co-Founder Tommy DiRaimondo, Ph.D. to Chief Scientific Officer
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
From Janux Therapeutics
Via Business Wire
News headline image
Janux Therapeutics Announces Pricing of $60 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
From Janux Therapeutics
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS